Coming Soon – October 2019

MARKET OUTLOOK

Scleroderma (systemic sclerosis [SSc]) is heterogeneous disease characterized by a combination of skin fibrosis, vasculopathies, lung disease (e.g., pulmonary arterial hypertension, pulmonary fibrosis) and other manifestations (e.g., renal crisis). Rheumatologists treat SSc on an individualized basis, depending on the severity of the patient’s disease and the organs involved. No drugs are approved for SSc, but numerous drug classes are used to manage the symptoms, albeit typically with suboptimal results. Oral immunosuppressants are used to treat skin fibrosis and interstitial lung disease. Calcium-channel blockers, endothelin receptor agonists, PDE-5 inhibitors, and prostacyclin analogues are prescribed to manage vasculopathies, and several classes of therapies are prescribed for pulmonary arterial hypertension in SSc.

QUESTIONS ANSWERED

  • Which disease manifestations are most common among the SSc patient populations of surveyed rheumatologists? Which classes and drugs are most commonly prescribed for these key manifestations of SSc?
  • Which drugs are the patient-share leaders in SSc? How are branded drugs and biologics positioned in surveyed physicians’ treatment algorithms?
  • Boehringer Ingelheim’s Ofev is advancing in the late-phase pipeline to treat lung disease in SSc; how do clinicians currently manage lung disease?
  • What factors drive movement of SSc patients through lines of therapy?
  • What are the most influential drivers of treatment selection in SSc?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Coming Soon
      • Coming Soon

Author(s): John Crowley

John Crowley, ,  is an analyst in the CNS disorders group at Decision Resources. Prior to joining the company, Dr. Crowley was a postdoctoral associate at Harvard Medical School, where he studied mechanisms regulating the strength and dynamics of synaptic connections. He earned a from the University of Massachusetts Medical School, where he conducted research on the modulation of ion channel function by membrane lipids, and a from Worcester Polytechnic Institute.


Related Reports

Scleroderma (Systemic Sclerosis) | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees...

View Details